Modeling Defective Interfering Virus Therapy for AIDS Conditions for DIV Survival
The administration of a genetically engineered defective interfering virus (DIV) that interferes with HIV-1 replication has been proposed as a therapy for HIV-1 infection and AIDS. The proposed interfering virus, which is designed to superinfect HIV-1 infected cells, carries ribozymes that cleave conserved regions in HIV-1 RNA that code for the viral envelope protein. Thus DIV infection of HIV-1 infected cells should reduce or eliminate viral production by these cells. The success of this therapeutic strategy will depend both on the intercellular interaction of DIV and HIV-1, and on the overall dynamics of virus and T cells in the interaction of HIV-1, DIV and CD4$^+$ T cells {\it in vivo.} The results of both mathematical analysis and numerical simulation indicate that survival of the engineered DIV purely on a peripheral blood HIV-1 infection is unlikely. However, analytical results indicate that DIV might well survive on HIV infected CD4$^+$ T cells in lymophoid organs such as lymph nodes and spleen, or on other HIV-1 infected cells in these organs.
Year of publication: |
1993-08
|
---|---|
Authors: | Nelson, George W. ; Perelson, Alan S. |
Institutions: | Santa Fe Institute |
Saved in:
Saved in favorites
Similar items by person
-
Dynamics of One-Pass Germinal Center Models: Implications for Affinity Maturation
Nimwegen, Erik van, (1998)
-
Towards a General Function Describing T Cell Proliferation
DeBoer, Rob J., (1994)
-
Base Pairing Probabilities in a Complete HIV-1 RNA
Huynen, Martijn A., (1995)
- More ...